You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARYThe goal of this proposal is to optimize and clinically validate a new diagnostic test for eosinophilic chronic rhinosinusitis (eCRS) at the point-of-care, improving the efficiency, value, and accessibility of personalized medicine. eCRS affects up to 5 million Americans and is characterized by varying degrees of sinonasal and peripheral eosinophilia, linked to treatment responsiven ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. A Precision Medicine for Alcohol-Associated Liver Disease

    SBC: GENETOBE INC            Topic: 150

    ABSTRACT The goal of this study is to develop an RNAi-based genetic precision medicine to treat alcohol associated liver disease (AALD). AALD is a devastating health problem worldwide, accounts for the majority of alcohol-related mortality globally and is the second most indication for liver transplantation in the US. The current medical management for AALD remains limited, and no proven pathobiol ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. PANK Activators for the treatment of pantothenate kinase-associated neurodegeneration

    SBC: Virtus Therapeutics Corporation            Topic: NINDS

    SUMMARY Pantothenate kinase-associated neurodegeneration, PKAN, is a rare progressive neurodegenerative disorder associated with iron accumulation in the brain. The disease causes early immobility and often death by early adulthood. PKAN is caused by mutations in one of four human pantothenate kinase genes, PANK2 gene, which encodes a mitochondrial pantothenate kinase. Consistent with the clinical ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Addressing the wireless power problem: A low-power hybrid radio for neuroscience experiments

    SBC: SPIKE NEURO LLC            Topic: 101

    Project Summary Closed-loop stimulation is key to the study and treatment of neurological disorders. However, largely due to current wireless power demands, stimulation systems are restricted to wired connections, which impact natural behavior, induce motion artifacts, and limit complexity of study design. While a few wireless recording- only systems have been developed, the power demands of these ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of the HC2099 series of MmpL3 inhibitors to treat tuberculosis

    SBC: TARN BIOSCIENCES, INC.            Topic: NIAID

    Tarn Biosciences, Inc. is a start-up pharmaceutical company headquartered in East Lansing, Michigan. The company is developing new therapies for tuberculosis (TB). The goal of this STTR is to develop the MmpL3 inhibitor, HC2099, as a new treatment for drug susceptible and multidrug-resistant TB (MDR-TB). In 2019, 10 million people worldwide fell ill to TB with ~ 1.4 million lives lost. Standard-of ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Leptospirosis Vaccine Development

    SBC: Luna Bioscience, Inc.            Topic: NIAID

    Summary/abstract. Leptospirosis is a globally important neglected disease caused by pathogenic Leptospira. It is estimated to cause more than 1 million global cases annually with a 5-20% case-fatality rate, significant morbidity, and important public health consequences. Currently there is no safe and effective vaccine to prevent human leptospirosis. LeptoX, Inc. proposes to develop the first huma ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of an empathetic chatbot to monitor perinatal mental health longitudinally

    SBC: Poisera, Inc.            Topic: 104

    1 ABSTRACT2 One in five pre- or postnatal women will develop a perinatal mood disorder (PMD). While temporary and3 treatable, 50-65% of mothers with PMD symptoms never receive a diagnosis or treatment due to inadequate4 screening practices. PMDs remain undetected because mothers do not trust clinicians due to fear of judgment,5 stigma, or even loss of parental rights. Untreated PMDs increase risk ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Antifungals targeting pantothenate phosphorylation

    SBC: CURATIX, LLC            Topic: NIAID

    SUMMARY Invasive fungal infections (IFIs) create significant healthcare and economic burdens as they are responsible for more than one billion infections worldwide each year resulting in more than 1.5 million deaths. Hospital patients who acquire nosocomial IFIs experience longer hospital stays, increased morbidity, and higher mortality rates. Only a few classes of antifungal drugs are available, ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Therapeutic Agents Targeting Cryptococcal Infections

    SBC: Quercus Molecular Design, LLC            Topic: NIAID

    Cryptococcus species are a clinically important group of opportunistic fungal pathogens that can cause life threatening disease, particularly in the immunocompromised patient population. Historically, this has involved patients with advanced HIV, but is becoming more prevalent in other immunovulnerable populations. The primary pathogens, C. neoformans and C. gattii, are ubiquitous in the environme ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel Technology to Disseminate WOOP (Wish, Outcome, Obstacle, Plan) to Dementia Caregivers

    SBC: BORROW MY GLASSES LLC            Topic: NIA

    1 Approximately 6.5 million Americans aged 65 and older live with dementia, supported by more than 11 million2 unpaid family caregivers. These numbers are projected to rise exponentially in the coming decades fueling the3 need to develop scalable ways to support dementia caregivers. The need to empower dementia caregivers to4 continue providing care while maintaining their own health and well-bein ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government